Chemoinformaics analysis of (16S)-Sarpagan-17-ol
| Molecular Weight | 294.398 | nRot | 1 |
| Heavy Atom Molecular Weight | 272.222 | nRig | 23 |
| Exact Molecular Weight | 294.173 | nRing | 6 |
| Solubility: LogS | -3.136 | nHRing | 5 |
| Solubility: LogP | 3.024 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 44 | No. of Aliphatic Hetero Cycles | 4 |
| No. of Heavy Atom | 22 | No. of Aromatic Carbocycles | 1 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 4 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 22 | No. of Saturated Hetero Cycles | 3 |
| No. of Carbon atom | 19 | No. of Saturated Rings | 3 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 9 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 10 |
| nHA | 2 | APOL | 49.4014 |
| nHD | 2 | BPOL | 24.3506 |
| QED | 0.794 |
| Synth | 5.134 |
| Natural Product Likeliness | 2.152 |
| NR-PPAR-gamma | 0.006 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.014 |
| Pgp-sub | 0.25 |
| HIA | 0.27 |
| CACO-2 | -4.946 |
| MDCK | 0.0000204 |
| BBB | 0.946 |
| PPB | 0.851515 |
| VDSS | 1.765 |
| FU | 0.119867 |
| CYP1A2-inh | 0.515 |
| CYP1A2-sub | 0.39 |
| CYP2c19-inh | 0.248 |
| CYP2c19-sub | 0.187 |
| CYP2c9-inh | 0.118 |
| CYP2c9-sub | 0.782 |
| CYP2d6-inh | 0.425 |
| CYP2d6-sub | 0.881 |
| CYP3a4-inh | 0.652 |
| CYP3a4-sub | 0.795 |
| CL | 9.175 |
| T12 | 0.344 |
| hERG | 0.032 |
| Ames | 0.067 |
| ROA | 0.893 |
| SkinSen | 0.163 |
| Carcinogencity | 0.922 |
| EI | 0.046 |
| Respiratory | 0.985 |
| NR-Aromatase | 0.005 |
| Antiviral | Yes |
| Prediction | 0.682648 |